International Agency for Research on Cancer (IARC) - Summaries & Evaluations
VOL.: 5 (1974) (p. 125)
5. Summary of Data Reported and Evaluation
5.1 Animal carcinogenicity data
Dieldrin was tested by the oral route only in mice and rats. The
hepatocarcinogenicity of dieldrin in the mouse has been demonstrated
and confirmed in several experiments, and some of the liver-cell
tumours were found to metastasize. A dose-response effect has been
demonstrated in both sexes with an increased tumour incidence in
females at the lowest dose tested, 0.15 ppm in the diet
(corresponding to about 0.01 mg/kg bw/day). In mice, there is no
evidence of carcinogenicity in organs other than the liver.
The available data in rats have not provided evidence of
carcinogenicity at levels of up to 50 ppm in the diet (corresponding
to an intake of about 2.5 mg/kg bw/day).
The experiments in dogs and monkeys were too limited in duration
and/or group sizes to allow any conclusions to be made.
5.2 Human carcinogenicity data
The epidemiological study carried out on occupationally exposed
workers does not allow any conclusions to be made concerning the
existence of an excess risk of developing cancer.
Although fat concentrations of dieldrin residues were higher in
terminal cancer patients than in control patients, this finding is
inconclusive as to a causal relationship.
Subsequent evaluation: Suppl. 7 (1987)
Last updated: 17 March 1998
Dieldrin (IARC Summary & Evaluation, Supplement 7, 1987)
Dieldrin (PIM 575)